Market Outlook:

NSCLC has one of the most dynamic drug development pipelines in oncology with multiple targeted and biomarker-driven therapies. DRG expects the NSCLC therapy market to experience robust growth throughout the 2017-2027 forecast period. The biggest driver of market sales growth will be the continued uptake and anticipated label expansions of immune checkpoint inhibitors. EGFR and ALK inhibitors will also contribute to market growth following the first-line label expansions of Tagrisso and Alecensa, respectively.

Questions Answered:

How large are the drug-treatable NSCLC populations and how will the drug-treatment rates change over time?

What is the current state of treatment in NSCLC? What are interviewed experts’ insights on current treatment options?

What clinical needs remain unfulfilled? What pipeline products are most promising, and what sales/uptake could they secure in NSCLC?

What therapies of note are progressing in earlier phases? What are the drivers and constraints in the NSCLC market, and how will the market evolve over the forecast period?

Product Description:

Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

 


Related Reports

Non-Small-Cell Lung Cancer - Current Treatment - Detailed Expanded Analysis: Treatment Sequencing (EU5)

This report is available to find out more click the link and fill out the form to get more details.

View Details

Non-Small-Cell Lung Cancer - Landscape & Forecast - Disease Landscape & Forecast

Non-small-cell lung cancer (NSCLC), a dynamic oncology indication with high unmet need remains a key area of focus for drug developers.

View Details

Non-Small-Cell Lung Cancer - Current Treatment - Detailed, Expanded Analysis (EU5) - 2020

The current treatment algorithm for non-small-cell lung cancer (NSCLC) is rapidly evolving. The increasing number of biomarker-driven therapies has r...

View Details

Non-Small-Cell Lung Cancer - Unmet Need - Detailed, Expanded Analysis - Metastatic Squamous NSCLC (US/EU)

The preferred initial treatment for metastatic squamous non-small-cell lung cancer (NSCLC), regardless of PD-...

View Details